María Candamo-Lourido

The paper identifies a Tankyrase scaffolding inhibitor, S8 (ARCher-142), that selectively targets the ARC4 peptide binding domain with 8 µM potency.

This study shows that the TNKS inhibitor OM-153 reduces fibrosis markers and ECM expression in multiple preclinical IPF models by inhibiting WNT/β-catenin and YAP signaling.

This study evaluates the relevance of sham control groups in preclinical cerebral ischemia studies by comparing protein profiles between sham and ischemic groups.